Protein Synthesis in Cancer Cells: Mechanisms and Novel Targeted Therapies (Volume II)
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: closed (31 July 2024) | Viewed by 346
Special Issue Editor
Interests: glioblastoma; glioma; ribosome biogenesis; nucleolus; p53; DNA damage response in cancer
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
This Special Issue is the second edition of "Protein Synthesis in Cancer Cells: Mechanisms and Novel Targeted Therapies" (https://www.mdpi.com/journal/cancers/special_issues/Protein_Synthesis).
In human cancers, oncogenes often induce rapid cell growth and proliferation, associated with an increase in protein synthesis. The synthesis of proteins is controlled at many levels. For example, the synthesis of proteins that affect cancer cell growth or confer resistance to treatment may be altered at the stage of translation initiation caused by changes in translation factors, or modifications of rRNA and tRNA. There are also more examples of cancer-associated changes in rRNA- or tRNA-modifying enzymes. Many existing and emerging anticancer therapeutic agents that inhibit cancer cell growth do so by interfering with nucleotide metabolism or RNA polymerase transcription, ultimately not only affecting DNA or RNA synthesis, but also mRNA translation. Recent studies have revealed connections between oncogene signaling, nucleotide metabolism, and ribosome biogenesis in different cancer types. In fact, cancer cells may become addicted to elevated rates of ribosome biogenesis, specific alterations in the ribosomal machinery, or deregulated translation. Such functional alterations that ultimately affect cancer cell protein synthesis and growth represent opportunities to develop novel anticancer therapies.
This Special Issue of Cancers, “Protein Synthesis in Cancer Cells: Mechanisms and Novel Targeted Therapies”, is devoted to compiling new research articles and timely reviews on the topic of protein synthesis in cancer cells. Specifically, we welcome submissions on cellular factors that induce protein synthesis, ribosome biogenesis machinery in cancer, RNA Pol I machinery, ribosomal stress and p53, ribosomal proteins, and how the translational machinery is corrupted in growing cancer cells through modifications on translation factors, tRNA, or rRNA. We also welcome studies on how translation can be targeted by present or emerging novel targeted therapeutics. Manuscripts dealing with the development of prognostic or predictive biomarkers related to ribosome biogenesis, the nucleolus, or mRNA translation in cancer are also of great interest.
Dr. Mikael S. Lindström
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- ribosome biogenesis
- cancer cell growth
- protein synthesis
- targeted therapy
- nucleolus
- Myc
- mTOR
- mRNA translation
- RNA polymerase I
- transcription inhibitor
- transfer RNA
- transfer RNA modification
- transfer-RNA-modifying enzymes
- ribosomal RNA
- eukaryotic translation initiation factor
- translation elongation
- ribosomal protein
- nucleolar stress
- nucleotide metabolism
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
